



PRIOR AUTHORIZATION REQUEST

Ilaris

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for ALL PA requests.

1	Will the requested medication be used in combination with another biologic agent for an inflammatory condition? [Note: Examples include Cimzia, Enbrel, Erelzi, Humira, Amjevita, Simponi SC, Simponi Aria, Remicade, Inflectra, Renflexis, Actemra (SC or IV), Kevzara, Orencia (SC or IV), Rituxan, Kineret, Stelara (SC or IV), Siliq, Cosentyx, Taltz, Tremfya, Arcalyst.] [If yes, no further questions.]	Yes	No
2	Is the patient currently receiving the requested medication? [If no, skip to question 8.]	Yes	No
3	Has the patient been receiving medication samples for the requested medication?	Yes	No

If you have any
questions, call:
1-888-258-8250

PRV 07.29.25.22

PRIOR AUTHORIZATION REQUEST

[If yes, skip to question 8.]

- | | | | |
|---|---|-----|----|
| 4 | <p>Does the patient have a previously approved PA on file with the current plan?
 [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]
 [If yes, skip to question 6.]</p> | Yes | No |
| 5 | <p>Has documentation been provided to confirm that the patient has had a clinically significant response? ACTION REQUIRED: Submit supporting documentation.
 [If yes, skip to question 8.]
 [If no, no further questions.]</p> | Yes | No |
| 6 | <p>What is the indication or diagnosis?</p> <p><input type="checkbox"/> Cryopyrin-associated periodic Syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome [MWS], and neonatal onset multisystem inflammatory disease [NOMID] or chronic infantile neurological cutaneous and articular [CINCA] syndrome) (If checked, go to 7)</p> <p><input type="checkbox"/> Familial Mediterranean fever (FMF) (If checked, go to 7)</p> <p><input type="checkbox"/> Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) (If checked, go to 7)</p> <p><input type="checkbox"/> Systemic juvenile idiopathic arthritis (SJIA) (If checked, go to 7)</p> <p><input type="checkbox"/> Tumor necrosis factor receptor associated periodic syndrome (TRAPS) (If checked, go to 7)</p> <p><input type="checkbox"/> Stills disease, adult onset [Note: If the patient is less than 18 years of age, select systemic juvenile idiopathic arthritis.] (If checked, go to 7)</p> <p><input type="checkbox"/> Rheumatoid arthritis (If checked, no further questions)</p> <p><input type="checkbox"/> COVID-19 (Coronavirus Disease 2019) [Note: This includes requests for cytokine release syndrome associated with COVID-19.] (If checked, no further questions)</p> <p><input type="checkbox"/> Other (If checked, no further questions)</p> | | |
| 7 | <p>How long has the patient been receiving the requested therapy?</p> <p><input type="checkbox"/> Less than 3 months (If checked, go to 8)</p> <p><input type="checkbox"/> Greater than or equal to 3 months (If checked, go to 42)</p> | | |
| 8 | <p>What is the indication or diagnosis?</p> <p><input type="checkbox"/> Cryopyrin-associated periodic Syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome [MWS], and</p> | | |

**If you have any
questions, call:
1-888-258-8250**

PRV 07.29.25.22

PRIOR AUTHORIZATION REQUEST

neonatal onset multisystem inflammatory disease [NOMID] or chronic infantile neurological cutaneous and articular [CINCA] syndrome) (If checked, go to 9)

☐ Familial Mediterranean fever (FMF) (If checked, go to 15)

☐ Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) (If checked, go to 21)

☐ Systemic juvenile idiopathic arthritis (SJIA) (If checked, go to 28)

☐ Tumor necrosis factor receptor associated periodic syndrome (TRAPS) (If checked, go to 34)

☐ Stills disease, adult onset [Note: If the patient is less than 18 years of age, select systemic juvenile idiopathic arthritis.] (If checked, go to 25)

☐ Rheumatoid arthritis (If checked, no further questions)

☐ COVID-19 (Coronavirus Disease 2019) [Note: This includes requests for cytokine release syndrome associated with COVID-19.] (If checked, no further questions)

☐ Other (If checked, no further questions)

9	Is the patient greater than or equal to 4 years of age? [If no, no further questions.]	Yes	No
10	Is there laboratory evidence of a genetic mutation (such as in the Cold-Induced Autoinflammatory Syndrome 1 [CIAS1 also referred to as the NLRP-3])? [If no, no further questions.]	Yes	No
11	Does the patient have elevated inflammatory markers (C-reactive protein [CRP] and serum amyloid A)? [If no, no further questions.]	Yes	No
12	Does the patient have AT LEAST TWO of SIX typical Cryopyrin-associated periodic Syndromes (CAPS) manifestations: A) Urticaria-like rash, B) Cold-triggered episodes, C) Sensorineural hearing loss, D) Musculoskeletal symptoms, E) Chronic aseptic meningitis, F) Skeletal abnormalities? [If no, no further questions.]	Yes	No
13	Does the patient have functional impairment limiting the activities of daily living? [If no, no further questions.]	Yes	No
14	Is the requested medication being prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or dermatologist? [If yes, skip to question 38.] [If no, no further questions.]	Yes	No

**If you have any
questions, call:
1-888-258-8250**

PRV 07.29.25.22

PRIOR AUTHORIZATION REQUEST

15	Is the requested medication being prescribed by or in consultation with a rheumatologist, nephrologist, geneticist, gastroenterologist, oncologist, or hematologist? [If no, no further questions.]	Yes	No
16	Is the patient greater than or equal to 2 years of age? [If no, no further questions.]	Yes	No
17	Does the patient have a failure, contraindication, or intolerance to colchicine? [If yes, skip to question 19.]	Yes	No
18	Will the patient be using the requested medication in combination with colchicine? [If no, no further questions.]	Yes	No
19	Prior to starting the requested medication, is the patient's C-reactive protein level GREATER OR EQUAL TO 10 mg/L OR elevated to AT LEAST TWO times the upper limit of normal for the reporting laboratory? [If no, no further questions.]	Yes	No
20	Prior to starting the requested medication, does the patient have a history of AT LEAST ONE flare per month despite use of colchicine OR was hospitalized for a severe flare? [If yes, skip to question 40.] [If no, no further questions.]	Yes	No
21	Is the requested medication being prescribed by or in consultation with a rheumatologist, nephrologist, geneticist, gastroenterologist, oncologist, or hematologist? [If no, no further questions.]	Yes	No
22	Is the patient greater than or equal to 2 years of age? [If no, no further questions.]	Yes	No
23	Prior to starting the requested medication, is the patient's C-reactive protein level GREATER OR EQUAL TO 10 mg/L OR elevated to AT LEAST TWO times the upper limit of normal for the reporting laboratory? [If no, no further questions.]	Yes	No
24	Prior to starting the requested medication, does the patient have a history of AT LEAST THREE febrile acute flares within the previous 6-month period OR was hospitalized for a severe flare? [If yes, skip to question 40.] [If no, no further questions.]	Yes	No
25	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No

**If you have any
questions, call:
1-888-258-8250**

PRV 07.29.25.22

PRIOR AUTHORIZATION REQUEST

26	<p>Is the request medication being prescribed by or in consultation with a rheumatologist? [If no, no further questions.]</p>	Yes	No
27	<p>Has the patient had a trial and failure, contraindication or intolerance to ALL of the following: A) Corticosteroids for AT LEAST 3 months, B) Conventional synthetic DMARD for AT LEAST 3 months, C) Nonsteroidal anti-inflammatory drugs for AT LEAST 3 months? [If yes, skip to question 40.] [If no, no further questions.]</p>	Yes	No
28	<p>Is the patient greater than or equal to 2 years of age? [If no, no further questions.]</p>	Yes	No
29	<p>Is the requested medication being prescribed by or in consultation with a rheumatologist? [If no, no further questions.]</p>	Yes	No
30	<p>Has the patient tried AT LEAST TWO systemic agents for this condition for AT LEAST 3 MONTHS? [Note: Examples of one other systemic agent tried include a corticosteroid (oral, IV), a conventional synthetic DMARD (for example, methotrexate [MTX], leflunomide, sulfasalazine)] [If yes, skip to question 32.]</p>	Yes	No
31	<p>Has documentation been provided to confirm that the patient has an intolerance to AT LEAST TWO agents? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of one other systemic agent tried include a corticosteroid (oral, IV), a conventional synthetic DMARD (for example, methotrexate [MTX], leflunomide, sulfasalazine).] [If no, no further questions.]</p>	Yes	No
32	<p>Has documentation been provided to confirm that the patient has an intolerance, contraindication to, or failed treatment for AT LEAST 3 months with preferred TNF inhibitors, Enbrel (etanercept) and an adalimumab product (Hadlima, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]</p>	Yes	No
33	<p>Has documentation been provided to confirm that the patient has an intolerance, contraindication to, or failed treatment for AT LEAST 3 months with preferred JAK inhibitor, Xeljanz? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 40.] [If no, no further questions.]</p>	Yes	No
34	<p>Is the requested medication being prescribed by or in consultation with a rheumatologist, nephrologist, geneticist, gastroenterologist, oncologist, or hematologist? [If no, no further questions.]</p>	Yes	No

**If you have any
questions, call:
1-888-258-8250**

PRV 07.29.25.22

PRIOR AUTHORIZATION REQUEST

35	Is the patient greater than or equal to 2 years of age? [If no, no further questions.]	Yes	No
36	Prior to starting the requested medication, is the patient's C-reactive protein level GREATER OR EQUAL TO 10 mg/L OR elevated to AT LEAST TWO times the upper limit of normal for the reporting laboratory? [If no, no further questions.]	Yes	No
37	Prior to starting the requested medication, does the patient have a history of AT LEAST SIX flares per year period OR was hospitalized for a severe flare? [If yes, skip to question 40.] [If no, no further questions.]	Yes	No
38	Will the requested medication be used in combination with biologics or DMARDs? [If yes, no further questions.]	Yes	No
39	Does the requested dose exceed Food and Drug Administration (FDA) approved label dosing for the indication? [No further questions.]	Yes	No
40	Will the requested medication be used in combination with biologics or DMARDs? [If yes, no further questions.]	Yes	No
41	Does the requested dose exceed Food and Drug Administration (FDA) approved label dosing for the indication? [No further questions.]	Yes	No
42	Has the patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug), when assessed by at least one objective measure? [Note: Examples of objective measures include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (for example, C-reactive protein, amyloid A), reduction in proteinuria, and/or stabilization of serum creatinine.] [If yes, no further questions.]	Yes	No
43	Has the patient experienced an improvement from baseline (prior to initiating the requested drug) in AT LEAST ONE symptom, such as fewer cold-induced attacks; less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:



PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.